

<b>NCT ID</b>	NCT06185556
<b>Title</b>	COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-12-29
<b>Location</b>	Netherlands
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06176885
<b>Title</b>	Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-12-20
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Camrelizumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06152523
<b>Title</b>	Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-11-30
<b>Location</b>	France
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	Monalizumab/MEDI5257
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT06149481
<b>Title</b>	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-11-29
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	N-803, Retifanlimab, SX-682
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06120127
<b>Title</b>	Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
<b>Phase</b>	Phase 2

<b>Date Added</b>	2023-11-07
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Chemotherapy, PD-1 antibody
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06106308
<b>Title</b>	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-10-30
<b>Location</b>	Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bevacizumab, FOLFIRI, FOLFOX, Onvansertib
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06107413
<b>Title</b>	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-10-30

<b>Location</b>	Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States Oregon, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan South Korea Spain Taiwan
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06105021
<b>Title</b>	Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-10-27
<b>Location</b>	California, United States Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AFNT-211
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06102902
<b>Title</b>	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-10-26
<b>Location</b>	California, United States Colorado, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States

<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	BET Bromodomain Inhibitor ZEN-3694, encorafenib
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06099821
<b>Title</b>	KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-10-25
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	apatinib, KN046, Regorafenib
<b>Tags</b>	MSI-H/ MMRd